Top

Journal of Cancer Survivorship

Published in:

01-03-2009

Survivorship considerations in adults with hereditary breast and ovarian cancer syndrome: state of the science

Authors: Cheryl B. Crotser, Marcia Boehmke

Published in: Journal of Cancer Survivorship | Issue 1/2009

Abstract

Introduction

Five to 10% of breast cancers are caused by inherited mutations of the BRCA1/2 genes. Knowledge of inherited risk for cancer has potential for psychosocial consequences. The purpose of this review is to determine the survivorship concerns of women with mutations of BRCA1/2; with and without a diagnosis of cancer.

Methods

The search strategy included a search of CINAHL, PsycINFO, Medline, Pubmed, and Cochrane databases to identify research reports with specific aims of determining physical, psychosocial or spiritual outcomes of genetic testing for breast and ovarian cancer syndrome in adults at high risk for BRCA1/2 mutations. The identified studies were analyzed by design, sampling, and outcome measures. They were categorized by domain and main findings by domain are summarized.

Results

One systematic review, ten qualitative and 27 quantitative studies met the inclusion criteria. Four theoretical frameworks were identified.

Discussion/Conclusions

Survivorship concerns were multidimensional and included issues related to risk reduction procedures, psychological and emotional impacts, and impact on family and social relationships. Many adults experience temporary distress after receipt of positive BRCA1/2 testing. Usually the distress is not clinically significant, however support is desired from health professionals, others who have a BRCA1/2 mutation, and family as decisions are made regarding screening and risk-reducing options. Social relationships are impacted as information is communicated to family members. Limitations of the current state of the science, opportunities to build evidence for the future and implications for nursing practice and education are identified.

American Cancer Society. Breast Cancer Facts and Figures 2007–2008 (2007). Available from: www.cancer.org/docroot/STT/stt_0.asp.

National Cancer Institute Genetics of breast and ovarian cancer. 2005 Available at www.cancer.gov/cancertopics/pdq/genetics/breast-and-ovarian/healthprofessional.

Kessler L, Collier A, Brewster K, Smith C, Weathers B, Wileyto E, et al. Attitudes about genetic testing and genetic testing intentions in African American women at increased risk for hereditary breast cancer. Genet Med. 2005;7:230–8.PubMed

National Comprehensive Cancer Network. Genetic/Familial High-Risk Assessment: Breast and Ovarian. 2007. Available from: http://www.nccn.org/professionals/physician_gls/PDF/genetics_screening.pdf. Accessed on February 18, 2008.

Warner E, Plewes D, Hill K, Causer P, Zubovitis J, Jong R, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast exam. JAMA. 2004;292:1317–25.PubMedCrossRef

Webster’s College Dictionary USA: Random House, 1991.

Farmer B, Smith E. Breast cancer survivorship: are African American women considered? A concept analysis. Oncol Nurs Forum. 2002;29:779–87.PubMedCrossRef

Ferrell B, Grant M, Funk B, Otis-Green S, Garcia N. Quality of life in breast cancer survivors as identified by focus groups. Psycho-Oncol. 1997;6:13–23.CrossRef

Hamilton R, Bowers B. The theory of genetic vulnerability: a Roy model exemplar. Nurs Sci Q. 2007;20:254–65.PubMedCrossRef

10.

Rolland J, Williams J. Toward a biopsychosocial model for 21st century genetics. Fam Proc. 2005;44:3–24.CrossRef

11.

O’Neill SC, DeMarco T, Peshkin BN, Roger S, Rispoli J, Brown K, et al. Tolerance for uncertainty and perceived risk among women receiving uninformative BRCA1/2 test results. Am J Med Genet C. 2006;142:251–9.

12.

Claes E, Evers-Kiebooms G, Decruyenaere M, et al. Surveillance behavior and prophylactic surgery after predictive testing for hereditary breast/ovarian cancer. Behav Med. 2005;31(3):93–105.PubMedCrossRef

13.

Speice J, McDaniel S, Rowley P, Loader S. Family issues in a psychoeducation group for women with a BRCA mutation. Clin Genet. 2002;62:121–7.PubMedCrossRef

14.

Kenen R, Ardern-Jones A, Eeles R. Social separation among women under 40 years of age diagnosed with breast cancer and carrying a BRCA1 or BRCA2 mutation. J Genet Couns. 2006;15:149–62.PubMedCrossRef

15.

Sankar P, Cho MK, Wolpe PR, Schairer C. What is in a cause? Exploring the relationship between genetic cause and felt stigma. Genet Med. 2006;8:33–42.PubMedCrossRef

16.

D’Agincourt-Canning L. Genetic testing for hereditary breast and ovarian cancer: responsibility and choice. Qual Health Res. 2006;16:97–118.PubMedCrossRef

17.

Appleton S, Fry A, Rees G, Rush R, Cull A. Psychosocial effects of living with an increased risk of breast cancer: an exploratory study using telephone focus groups. Psycho-Oncol. 2000;9:511–21.CrossRef

18.

Lloyd S, Watson M, Oaker G, Sacks N, Rovere U, Gui G. Understanding the experience of prophylactic bilateral mastectomy: a qualitative study of ten women. Psycho-Oncol. 2000;9:473–85.CrossRef

19.

Kenen RH, Shapiro PJ, Hantsoo L, Friedman S, Coyne JC. Women with BRCA1 or BRCA2 mutations renegotiating a post-prophylactic mastectomy identity: self-image and self-disclosure. J Genet Cousel. 2007;16:789–98.CrossRef

20.

Hallowell N, Foster C, Eeles R, Ardern-Jones A, Watson M. Accommodating risk: responses to BRCA1/2 genetic testing of women who have had cancer. Soc Sci Med. 2004;59:553–65.PubMedCrossRef

21.

Lim J, Macluran M, Price N, Bennett B, Butow P. Short and long-term impact of receiving genetic mutation results in women at increased risk for hereditary breast cancer. J Genet Couns. 2004;13:115–33.PubMedCrossRef

22.

Bonadona V, Saltel P, Desseigne F, et al. Cancer patients who experienced diagnostic genetic testing for cancer susceptibility: reactions and behavior after the disclosure of a positive test result. Cancer Epidemiol Biomarkers Prev. 2002;11(1):97–104.PubMed

23.

Kenen K, Ardern-Jones A, Eeles, R. Living with chronic risk: healthy women with a family history of breast/ovarian cancer. Health Risk Soc. 2003;5:315–31.CrossRef

24.

Esplen MJ, Hunter J, Leszcz M, Warner E, Narod S, Metcalfe K, et al. A multicenter study of supportive-expressive group therapy for women with BRCA1/BRCA2 mutations. Cancer. 2004;10:2327–40.CrossRef

25.

McKinnon W, Naud S, Ashikaga T, Collett R, Wood M. Results of an intervention for individuals and families with BRCA mutations: a model for providing medical updates and psychosocial support following genetic testing. J Genet Couns. 2007;16:433–56.PubMedCrossRef

26.

Bish A, Sutton S, Jacobs C, Levene S, Famirez A, Hodgson S. Changes in psychological distress after cancer genetic counseling: a comparison of affected and unaffected women. Br J Cancer. 2002;86:43–50.PubMedCrossRef

27.

Claes E, Evers-Klebooms G, Boogaerts A, Legius E. Diagnostic genetic testing for hereditary breast and ovarian cancer in cancer patients: women’s looking back on the pre-test period and a psychological evaluation. Genet Test. 2004;8:13–21.PubMedCrossRef

28.

Claes E, Evers-Klebooms G, Denayer L, Boogaerts A, Phillipe K, Legius E. Predictive genetic testing for hereditary breast and ovarian psychological distress and illness representations 1 year following disclosure. J Genet Couns. 2005;14:349–63.PubMedCrossRef

29.

Kinney A, Bloor L, Mandal D, Simonsen S, Baty B, Holubkov R, et al. The impact of receiving genetic test results on general and cancer-specific psychologic distress among members of an African–American kindred with a BRCA1 mutation. Cancer. 2005;104:2508–16.PubMedCrossRef

30.

Meiser B, Buto P, Schieden V, Gattas M, Gaff C, Harrop K, et al. Psychological adjustment of women at increased risk of developing hereditary breast cancer. Psychol Health Med. 2000;5(4):377–88.CrossRef

31.

Meiser B, Butow P, Friedlander M, Barrat A, Schnieden V, Watson M, et al. Psychological impact of genetic testing in women from high-risk cancer families. Eur J Cancer. 2002;38:2025–31.PubMed

32.

Smith KR, West JA, Croyle RT, Botkin JR. Familial context of genetic testing for cancer susceptibility: moderating effects of siblings’ test results on psychological distress 1 to 2 weeks after BRCA1 mutation testing. Cancer Epidemiol Biomarkers Prev. 1999;8:385–92.PubMed

33.

Stroup AM, Smith KR. Familial effects of BRCA1 genetic mutation testing: changes in perceived family functioning. Cancer Epidemiol, Biomarkers Prev. 2007;16:135–41.CrossRef

34.

Van Roosmalen M, Stalmeie P, Verhoef L, Hoekstra-Weebers J, Oosterwijk J, Hoogerbrugge N, et al. Impact of BRCA1/2 testing and disclosure of a positive test result on women affected and unaffected with breast or ovarian cancer. Am J Med Genet A. 2003;123:346–55.

35.

Bresser PJC, Van Gool AR, Seynaeve C, et al. Who is prone to high levels of distress after prophylactic mastectomy and/or salpingo-ovariectomy? Ann Oncol. 2007;18(10):1641–5.PubMedCrossRef

36.

Bresser PJC, Seynaeve C, Van Gool AR, et al. The course of distress in women at increased risk of breast and ovarian cancer due to an (identified) genetic susceptibility who opt for prophylactic mastectomy and/or salpingo-oophorectomy. Eur J Cancer. 2007;43(1):95–103.PubMedCrossRef

37.

Lodder L, Frets PG, Trijsburg RW, Meijers-Heijboer EJ, Klijn J, Seynaeve C, et al. One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: Emotional impact of the test outcome and decisions on risk management. Breast Cancer Res Treat. 2002;7:97–112.CrossRef

38.

Madalinska JB, Hollenstein J, Bleiker E, van Beurden M, Valdimarsdottir HB, Massuger LF, et al. Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J Clin Oncol. 2005;23:6890–8.PubMedCrossRef

39.

Metcalfe KA, Liede A, Trinkaus M, Hanna D, Narod SA. Evaluation of the needs of spouses of female carriers of mutations in BRCA1 and BRCA2. Clin Genet. 2002;62:464–9.PubMedCrossRef

40.

Schwartz MD, Peshkin BN, Hughes C, Main D, Isaacs C, Lerman C. Impact of BRCA1/BRCA2 mutation testing on psychologic distress in a clinic based sample. J Clin Oncol. 2002;20:514–20.PubMedCrossRef

41.

Tercyak KP, Peshkin BN, Brogan BM, et al. Quality of life after contralateral prophylactic mastectomy in newly diagnosed high-risk breast cancer patients who underwent BRCA1/2 gene testing. J Clin Oncol. 2007;25(3):285–91.PubMedCrossRef

42.

Van Oostrom I, Meijers-Heijboer H, Lodder LN, Duivenvoorden HJ, van Gool AR, Seynaeve C, et al. Long-term psychological impact of carrying a BRCA1/2 mutation and prophylactic surgery: a 5-year follow-up study. J Clin Oncol. 2003;21:3867–74.PubMedCrossRef

43.

DiProspero L, Seminsky M, Honeyford J, Doan B, Franssen E, Meschino W, et al. Psychosocial issues following a positive result of genetic testing for BRCA1 and BRCA2 mutations: findings from a focus group and a needs-assessment survey. CMAJ. 2001;164:1005–9.

44.

Dorval M, Patenaude A, Schneider K, Kieffer S, DiGianni L, Kalkbrenner K, et al. Anticipated versus actual emotional reactions to disclosure of results of genetic tests for cancer susceptibility: Findings from p53 and BRCA1 testing programs. J Clin Oncol. 2000;18:2135–42.PubMed

45.

Heemskerk-Gerritsen B, Brekelmans C, Menke-Pluymers M, van Geel A, Tilanus-Linthorst M, Bartels C, et al. Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam family cancer clinic. Ann Surg Oncol. 2007;14(12):3335–44.PubMedCrossRef

46.

Wagner TMU, Moslinger R, Langbauer G, Ahner R, Fleischmann E, Auterith A, et al. Attitude towards prophylactic surgery and effects of genetic counseling in families with BRCA mutations. Br J Cancer. 2000;82:1249–53.PubMedCrossRef

47.

McInerney-Leo A, Biesecker BB, Hadley DW, Kase RG, Giambarresi TR, Johnson E, et al. BRCA1/2 testing in hereditary breast and ovarian cancer families II: impact on relationships. Am J Med Genet. 2005;133:165–9.CrossRef

48.

Van Oostrom I, Meijers-Heijboer H, Lodder LN, Duivenvoorden HJ, Brocker-Vriends A, van Asperen CJ, et al. A prospective study of the impact of genetic susceptibility testing for BRCA1/2 or HNPCC on family relationships. Psycho Oncol. 2007;16:320–8.CrossRef

49.

Baum A, Friedman A, Zakowski S. Stress and genetic testing for disease risk. Health Psychol. 1997;16:8–19.PubMedCrossRef

50.

Johnson J. Self-regualtion theory and coping with physical illness. Research Nurs Health. 1999;22:435–48.CrossRef

51.

Lombusto I, Carbine N, Wallace J, Ezzo J. Prophylactic mastectomy for the prevention of breast cancer. The Cochrane Database of Systematic Reviews 2008 (4). Art No.: CD002748. doi: 10:1002/14651858.CD002748.pub2

Title: Survivorship considerations in adults with hereditary breast and ovarian cancer syndrome: state of the science
Authors: Cheryl B. Crotser
Marcia Boehmke
Publication date: 01-03-2009
Publisher: Springer US
Published in: Journal of Cancer Survivorship / Issue 1/2009
Print ISSN: 1932-2259
Electronic ISSN: 1932-2267
DOI: https://doi.org/10.1007/s11764-008-0077-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Methods

Results

Discussion/Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2009

Preventive health services and lifestyle practices in cancer survivors: a population health investigation

Self-reported global function among adult survivors of childhood lower-extremity bone tumors: a report from the Childhood Cancer Survivor Study (CCSS)

The LIVESTRONG Survivorship Center of Excellence Network

Quality health care for cancer survivors: A survivor’s perspective

Marriage after cancer in older adulthood

Screening mammography rate and predictors following treatment for colorectal cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer